# Tempus AI, Inc.

**TEM**

Nasdaq; business equipment; SIC 7370, Services-Computer Programming, Data Processing, Etc.; CIK 0001717115

# None

### No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.91 AUC<br>filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| **Peer failure rate** | 1.01% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $591M to $2.67B assets<br>total assets $2.3B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | thin data<br>not computable: dilution, distress, fortress balance sheet |
| **Inputs computable** | 3 of 14 |
| **Graded from** | filings received through Feb 24, 2026<br>255 days before the rescan; latest periodic filing 10-Q received Nov 2, 2026 |
| **Last close** | $70.39<br>2026-11-05; market equity $0; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 24, 2026*

We endeavor to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence, or AI, in healthcare. Intelligent Diagnostics use AI, including generative and agentic AI, to make laboratory tests more accurate, tailored, and personal. We make tests intelligent by connecting laboratory results to a patient's own clinical data, thereby personalizing the results.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 81.8** | | | | | | |
| Gross profitability | not computable | 28.7% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 11.4% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (1.7%) | (7.3%) | 81.8 | 618 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.3 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 47.8** | | | | | |
| Twelve-month failure probability | not computable | 0.05% | | | |
| *liabilities and a nearby cover-page share count are required at 2026-09-30* | | | | | |
| Altman Z double-prime | (1.60) | 2.18 | 65.8 | 565 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.08x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | 3.77x | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 3.13x | 2.01x | 29.8 | 663 | 2025-12-31 |
| **Growth and financing** | | | | | |
| Revenue growth, three-year compound | not computable | 6.4% | | | |
| *four annual observations are required; found 2* | | | | | |
| Free cash flow growth, three-year compound | not computable | 18.0% | | | |
| *four consecutive annual FCF observations are required; found 2* | | | | | |
| Reinvestment rate | not computable | 13.5% | | | |
| *NOPAT must exceed $100,000* | | | | | |
| Asset growth, three years | not computable | 5.1% | | | |
| *four annual observations are required; found 2* | | | | | |
| Net share issuance, one year | not computable | 0.5% | | | |
| *two annual share counts are required; found 0* | | | | | |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 3 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-05 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (8.8%) | (2.0%) | 44 |
| Distance from 52-week high | (17.2%) | (37.7%) | 73 |
| EBIT to enterprise value | not computable | 1.8% | |
| Free cash flow yield | not computable | 3.0% | |
| Book value to price | not computable | 0.30 | |
| Sales to price | not computable | 0.33 | |
| Composite equity issuance, five years | not computable | 4.2% | |
| Relative strength against the sector, log excess return | (0.36) | (0.29) | 44 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $590.5M |
| Operating cash flow, four quarters | -$108.4M |
| Months of runway | 65.4 |
| Days since last periodic filing | 4 (10-Q received Nov 2, 2026) |
| Median daily dollar volume, 63 sessions | $440.2M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$245.0M | 2025-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$218.1M | 2025-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 3 | assets | us-gaap:Assets | $2.3B | 2025-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 4 | assets | us-gaap:Assets | $926.1M | 2024-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 5 | current assets | us-gaap:AssetsCurrent | $1.2B | 2025-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $372.4M | 2025-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$2.4B | 2025-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$252.9M | 2025-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 9 | book equity | us-gaap:StockholdersEquity | $491.3M | 2025-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 10 | liabilities | us-gaap:Liabilities | $1.8B | 2025-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 11 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.3B | 2025-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 12 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $693.4M | 2024-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 13 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $21.0M | 2025-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 14 | depreciation amortization | us-gaap:Depreciation | $32.1M | 2025-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 15 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$291.1M | 2025-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 16 | income tax | us-gaap:IncomeTaxExpenseBenefit | -$51.7M | 2025-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 17 | current assets | us-gaap:AssetsCurrent | $667.6M | 2024-12-31 | 2026-02-24 | 10-K | 26-066961 |
| 18 | current liabilities | us-gaap:LiabilitiesCurrent | $291.1M | 2024-12-31 | 2026-02-24 | 10-K | 26-066961 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.